http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
Esperion Therapeutics (ESPR) Partners with Neopharm to Commercialize NEXLETOL and NEXLIZET in Israel
View Older Stories
-
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
-
Esperion Therapeutics (ESPR): Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
-
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
-
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
-
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientifi
-
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
-
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
-
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
-
Esperion to Report Third Quarter 2024 Financial Results on November 7
-
Esperion Therapeutics (ESPR) EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
-
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
-
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
-
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
-
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
-
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Esperion to Report Second Quarter 2024 Financial Results on August 12
-
Esperion to Participate in Upcoming BTIG Biotech Conference
-
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
-
Esperion Therapeutics (ESPR) Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
-
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
-
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
-
Esperion to Participate in Upcoming June Investor Conferences
-
Esperion (ESPR) and Otsuka Report Bempedoic Acid Met Primary Endpoint in Phase 3 Trial
-
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
-
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
-
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Esperion Reports First Quarter 2024 Financial Results
-
Esperion to Participate in Upcoming May Investor Conferences
-
Esperion to Report First Quarter 2024 Financial Results on May 7
-
Esperion Therapeutics (ESPR) Presents Important New Data from CLEAR Outcomes at ACC.24
-
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with
-
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
-
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
-
Esperion Therapeutics (ESPR) Reports Data from CLEAR Outcomes Sub-Groups as Poster Presentations
-
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
-
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
-
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of St
-
Esperion Therapeutics (ESPR) Announces FDA Approval of New Labels for NEXLETOL and NEXLIZET
-
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
-
Esperion Therapeutics (ESPR) Receives Positive CHMP Opinion for Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination
-
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular
-
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
-
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
-
Esperion Therapeutics (ESPR) Prices 56.7M Share Offering at $1.50/sh
-
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
-
Esperion Therapeutics (ESPR) Announces Proposed Public Offering of Common Stock
-
Esperion Announces Proposed Public Offering of Common Stock
